Brief: Supernus Pharmaceuticals Posts Q4 revenue USD 23.6 million
28/02/2023 21:15
Feb 28 (Reuters) - Supernus Pharmaceuticals Q4 revenue USD 23.6 million. * Q4 adjusted operating earnings USD 57.6 million * Q4 operating earnings USD 34.3 million * Outlook FY operating earnings USD -50 to -25 million * Outlook FY revenue USD 580-620 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing